Side-by-side · Research reference
CartalaxvsThymosin α-1
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED10/32 cited
BPhase 3HUMAN-REVIEWED8/39 cited
Cartalax
Bioregulator Peptide · Khavinson School
SQ · Protocol Unspecified
Thymosin α-1
Immune modulator · Approved (some countries)
SQ · 2× weekly · 6+ months for chronic indications
01Mechanism of Action
Parameter
Cartalax
Thymosin α-1
Primary target
Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023
Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001
Pathway
Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023
TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007
Downstream effect
Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023Povorozniuk 2007
Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007
Feedback intact?
—
—
Origin
Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007
Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001
Antibody development
—
—
02Dosage Protocols
Parameter
Cartalax
Thymosin α-1
Animal model dose
Unspecified (cartilaginous tissue extract protocol)
Rat study; extract preparation details not indexed in available abstracts.
—
Human dosing
Not established in PubMed-indexed literature
Russian-tradition protocols exist but lack peer-reviewed Western validation.
—
Frequency
—
2× weekly (Mon/Thu typical)
Lower / starter dose
—
0.8 mg per injection
Duration
—
6–12 months for chronic indications
Reconstitution
—
Sterile water for injection per vial label
Timing
—
No specific time
Half-life
—
~2 hours plasma; tissue effect days
03Metabolic / Fat Loss Evidence
Parameter
Cartalax
Thymosin α-1
Fat loss evidence
None — primary target is cartilage and bone tissue, not adipose
—
04Side Effects & Safety
Parameter
Cartalax
Thymosin α-1
Documented adverse effects
None reported in indexed animal studies
—
Human safety data
Not available in PubMed-indexed literature
—
Injection site reaction
—
Erythema, mild discomfort
GI symptoms
—
Rare nausea
Fatigue
—
Common during initial weeks
Fever / flu-like
—
Mild interferon-like response possible
Autoimmune
—
Theoretical risk; caution in active autoimmune disease
Cancer risk
—
No signal — used as adjuvant in oncology
Pregnancy / OB
—
Avoid
Absolute Contraindications
Cartalax
- ·Unknown due to lack of human clinical trial data
Thymosin α-1
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
- ·Concurrent immunosuppressant therapy (transplant patients)
Relative Contraindications
Cartalax
- ·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
Thymosin α-1
- ·Active autoimmune disease
- ·Severe immunocompromised state without supervision
05Administration Protocol
Parameter
Cartalax
Thymosin α-1
1. Route
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.
2. Frequency
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Storage
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
2× weekly, e.g. Monday + Thursday.
4. Storage
—
Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.
5. Needle
—
27–31G, 4–8 mm insulin syringe.